pH-D Feminine Health Launches First FDA-Cleared Phase 3 Clinical Trial for Boric Acid Suppositories
pH-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to clinically validate boric acid suppositories as a potential treatment of yeast infections, with the intent to support submission of a New Drug Application (NDA). https://mma.prnewswire.com/media/2749105/pH_D_Logo.jpg This pivotal […]